Quick Answer
LIPELLA PHARMACEUTICALS INC. reported Net Income of -$5.02 million for fiscal year 2024.
LIPELLA PHARMACEUTICALS INC. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2024 | -$5.02M | -8.6% |
| 2023 | -$4.62M | -77.8% |
| 2022 | -$2.60M | -39.3% |
| 2021 | -$1.87M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.25M | +13.2% | +5.5% |
| June 30, 2025 | -$1.33M | -41.5% | -1.6% |
| March 31, 2025 | -$1.31M | -9.6% | +9.6% |
| September 30, 2024 | -$1.44M | -9.1% | -54.0% |
| June 30, 2024 | -$938.1K | +39.0% | +21.3% |
| March 31, 2024 | -$1.19M | -11.6% | +10.0% |
| September 30, 2023 | -$1.32M | -85.4% | +14.0% |
| June 30, 2023 | -$1.54M | -96.8% | -44.1% |
- LIPELLA PHARMACEUTICALS INC. showed a decrease of -8.6% in Net Income compared to the prior fiscal year.
- Over the 2021–2024 period, LIPELLA PHARMACEUTICALS INC.’s net income has declined by 168.9% (from -$1.87 million to -$5.02 million).
- The most recent figure is from LIPELLA PHARMACEUTICALS INC.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 28, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: